Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT01031225 is registered in ClinicalTrials.gov with Synta Pharmaceuticals Corp. as lead sponsor.

NCT NCT01031225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01031225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Lead sponsor
Synta Pharmaceuticals Corp.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
February 28, 2014
Enrollment
113 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer